Pfizer's injection card Alferon ZAMI receives temporary approval from the US FDA

On November 11th, Hainan Puli Pharmaceutical Co., Ltd. announced that it has recently received temporary approval from the U.S. Food and Drug Administration for the injection of Canefisomide. Once the Canefisomide compound patent US9493582 held by Onyx Corporation expires on August 27, 2033, the company will be able to convert it to full approval and will be eligible to sell the injection of Canefisomide in the United States at that time.